CoChat

Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial

Open access
† · 2014 · The Lancet Diabetes & Endocrinology

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Background Long-term effects of behavioural weight loss interventions on diabetes complications are unknown. In a secondary analysis of the Look AHEAD (Action for Health in Diabetes) multicentre randomised clinical trial, we assessed whether an intensive lifestyle intervention (ILI) affects the development of nephropathy in people with type 2 diabetes.Methods Overweight or obese people aged 45-76 years with type 2 diabetes were randomly assigned (1:1) to ILI or to a diabetes support and education (DSE) group by a central web-based data management system, stratified by clinical centre and blocked with random block sizes. The ILI was designed to achieve and maintain weight loss through reduced caloric consumption and increased physical activity. The interventions were terminated early because of absence of effect on the primary outcome of cardiovascular disease events in the main Look AHEAD trial. Albuminuria and estimated glomerular filtration rate were prespecified as two of many other outcomes and were assessed from baseline until the interventions ended. They were combined post hoc to define the main outcome for this report, very-high-risk chronic kidney disease (CKD), based on the 2013 Kidney Disease Improving Global Outcomes (KDIGO) classification. Outcomes assessors and laboratory staff were masked to treatment, but participants and interventionists were not masked. Time-to-event data were analysed by intention to treat by the Kaplan-Meier method and proportional hazards models. The Look AHEAD trial is registered with ClinicalTrials.gov, NCT00017953.Findings Of the 5145 participants randomly assigned in the Look AHEAD trial (2570 to ILI and 2575 to DSE), analyses for very-high-risk CKD were done in 2423 (94%) of patients in the ILI group and 2408 (94%) of those in the DSE group. After a median of 8·0 years (IQR 7·9-9·9) of follow-up, the incidence of very-high-risk CKD was lower in the ILI group than in the DSE group, with incidence rates of 0·91 cases per 100 person-years in the DSE group and 0·63 per 100 person-years in the ILI group (difference 0·27 cases per 100 person-years, hazard ratio 0·69, 95% CI 0·55-0·87; p=0·0016). This effect was partly attributable to reductions in bodyweight, HbA1c, and systolic blood pressure. There were no safety concerns regarding kidney-related adverse events.Interpretation Weight loss should be considered as an adjunct to medical treatments to prevent or delay progression of CKD in overweight or obese people with type 2 diabetes.Funding National Institute of Diabetes and Digestive and Kidney Diseases.

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(14)70156-1

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 35 references

Research works printed but not linked: 1

  1. 2013, KDIGO clinical practice guideline for the valuation and management of chronic kidney disease, Kidney Int, 3, 1

Cited by

See all 347

Metadata

Authors
†
Corresponding author
†
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2014-10
Volume
2
Issue
10
Pages
801-809
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2413631339
Cited by
319
References
35
Citations by year
2026: 14 · 2025: 30 · 2024: 31 · 2023: 30 · 2022: 27 · 2021: 30 · 2020: 34 · 2019: 27 · 2018: 17 · 2017: 27 · 2016: 21 · 2015: 20 · 2014: 8
FWCI
20.03
Type
journal article
Language
en
Open access
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK56990, DK56992, DK57002, DK57008, DK57078, DK57131, DK57135, DK57136, DK57149, DK57151, DK57154, DK57171, DK57177, DK57178, DK57182, DK57219)
  • American Association of Clinical Endocrinologists
  • U.S. Department of Health and Human Services
  • Orexigen Therapeutics
  • Centers for Disease Control and Prevention
  • National Heart, Lung, and Blood Institute
  • National Institute of Nursing Research
  • Medtronic Foundation
  • Zafgen
  • Eisai
  • Novo Nordisk
  • AstraZeneca
  • National Center on Minority Health and Health Disparities
  • U.S. Department of Veterans Affairs
  • American Heart Association
  • Bristol-Myers Squibb
  • Sanofi
  • University of Pittsburgh (DK 046204, M01RR000056, UL1 RR 024153)
  • Boehringer Ingelheim
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
type 2 diabetes, diabetic nephropathy, chronic kidney disease, intensive lifestyle intervention, albuminuria, estimated glomerular filtration rate, Look AHEAD trial, diabetes support and education, overweight and obesity, long-term intervention effects, physical activity, caloric restriction, diabetes complications, cardiovascular disease prevention
MeSH terms
Aged, Diabetes Mellitus, Type 2, Female, Humans, Male, Middle Aged, Obesity, Risk Factors, Proportional Hazards Models, Overweight, Renal Insufficiency, Chronic, Weight Reduction Programs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. https://app.cochat.ai/papers/10.1016/s2213-8587(14)70156-1
The paper
†. (2014). Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(14)70156-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.